
MiMedx Group (MDXG) Stock Forecast & Price Target
MiMedx Group (MDXG) Analyst Ratings
Bulls say
MiMedx Group is facing temporary issues in the form of the recent PFS and OPPS schedule updates, which have impacted two of its four revenue streams but not its Advanced Surgical and international Wound Care segments. The company expects to incur a one-time restructuring charge in 2Q26, but is continuing to perform well and expects to see double-digit top-line growth in the long run. It has a strong track record and a best-in-class suite of clinical data, and is poised to outperform in the new environment with its vertically integrated manufacturing infrastructure and established sales force.
Bears say
MiMedx Group is facing several fundamental risks that could significantly impact its business. These include potential challenges related to tissue donorship, intense competition in the skin substitute market due to strict regulatory restrictions, and the potential termination or expiration of contracts with its major customers. Additionally, the company is facing reimbursement disruptions in the wound care space, resulting in a slow recovery for its Wound Care segment. These factors could lead to a decline in the company's top-line growth and have a negative impact on its financials and stock valuation.
This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.
MiMedx Group (MDXG) Analyst Forecast & Price Prediction
Start investing in MiMedx Group (MDXG)
Order type
Buy in
Order amount
Est. shares
0 shares